October 2018

Viela Bio Announces Late-Breaking Abstract Acceptance for VIB4920, a Novel Engineered CD40L Antagonist, at the 2018 ACR/ARHP Annual Meeting VIB4920 demonstrated proof-of-concept in a Phase 1b multiple-ascending dose study October...